Sunday, May 01, 2016 1:15:52 AM
?Posted by: Attila Lemos ?April 17, 2016 ?0
Medicine to treat lymphatic cancer will have subcutaneous version to minimize administration time. The new method allows the application of targeted therapy occurs in minutes.
linfoma_nao_hodgkin The course of treatment can transform the reality of patients with non-Hodgkin's lymphoma, an aggressive malignant lymphatic tumor that affects from children to the elderly. In Brazil, this type of cancer is responsible for killing more than 4000 people a year and have more than 10,000 new cases of the disease in 2016¹, according to the INCA.
Depending on the stage of the disease, treatment usually includes combination chemotherapy, radiotherapy and targeted therapy. However, the use of such therapeutic allies can subject the patient to a stressful and time consuming routine, due to the long time needed for the medication infusion. To decrease the therapeutic session, researchers at Roche, a world leader in health innovation, have created a new method of administration of rituximab drug, commercially known as MabThera a prescription drug. The new option allows the subcutaneous administration of the product, thereby lowering the drug administration period of about 2.5 hours to about 5 minutes.
Recently approved by ANVISA (National Health Surveillance Agency), the SC MabThera (rituximab subcutaneous) is the first monoclonal antibody of high complexity for treating lymphomas available in the subcutaneous version in the country. According to the SparkThera and Sabrina studies conducted in several countries, including Brazil, patients who used the subcutaneous version felt less worn and more comfortable with the application, feeling less pain and spending less time in clinics / hospitals.
According Lenio Alvarenga, medical director of Roche Farma Brazil, reducing the physical and psychological strain of the patient may considerably improve the treatment as a whole. "We know that the entire patient well-being is a key component of clinical best possible outcome for a patient. The arrival of MabThera SC is the constant pursuit of innovation by Roche, is bringing treatments for unmet medical needs or improving forms of treatment to help improve the lives of patients around the world, "he says.
Never argue with a fool, for after awhile, it becomes difficult to determine which is the fool.
Recent HALO News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/24/2024 08:05:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 10:49:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/18/2024 08:01:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/17/2024 08:03:48 PM
- Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis • PR Newswire (US) • 09/13/2024 05:30:00 PM
- Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer • PR Newswire (US) • 09/13/2024 12:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 09:56:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 08:12:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/11/2024 08:05:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/10/2024 08:16:18 PM
- Halozyme to Present at Upcoming Investor Conferences • PR Newswire (US) • 08/28/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 11:49:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 10:03:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/21/2024 08:11:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/20/2024 08:16:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2024 08:59:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/15/2024 08:31:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:57:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/14/2024 08:08:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/13/2024 08:19:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 08:07:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:03:09 PM
- HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS • PR Newswire (US) • 08/06/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:48:14 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM